A new ‘gut reset’ procedure helped GLP-1 users hold onto 80% of their weight loss after stopping
Losing weight on a GLP-1 drug turns out to be the easy part. Keeping it off is where things fall apart.
The moment many people stop taking medications like Ozempic or Zepbound, the weight starts coming back, a pattern now common enough to have a name: the ozempic rebound.
For years, there wasn’t much anyone could do about it outside of normal lifestyle changes. Now researchers believe they’ve pinpointed the exact spot in the body where the rebound begins, along with an experimental gut reset procedure built to target it.
If the early results hold, it could reshape what lasting ozempic weight loss actually looks like.
Why Ozempic weight loss doesn’t last after you stop
Most people don’t stay on these drugs for long. A 2024 JAMA Viewpoint estimated that 50 to 75% of users stop taking GLP-1 medications within 12 months.
The reasons vary. Cost is a major one. So are side effects and a simple reluctance to take a drug indefinitely.
The problem is what happens next. A 2026 University of Cambridge meta-analysis found that patients regain an average of 60% of their lost weight within a year of stopping. But the regain isn’t endless. It’s projected to taper off around 75% of the original loss, leaving most people holding onto about a quarter of what they shed.
But watching most of the progress reverse is demoralizing enough to feel like failure.
To understand the fix, it helps to understand the drugs. GLP-1 weight loss medications work by imitating the GLP-1 hormone, which regulates insulin and blood sugar, curbs appetite and slows digestion.
Take the drug away, and that artificial signal disappears. Appetite returns, digestion speeds up, and the body drifts back toward its old set point.
Here’s the key detail: the GLP-1 hormone these drugs mimic is made in the duodenum, the top section of the small intestine just below the stomach. That location is exactly what the new procedure goes after.
How the DMR “gut reset” procedure could change that
The procedure is called duodenal mucosal resurfacing, or DMR (informally, a “gut reset”).
It’s an outpatient treatment. A thin tube is threaded through the GI tract to the duodenum, and heat is delivered through it to burn away the unhealthy inner lining.
Because the resurfacing happens at the precise spot where those appetite-regulating hormones are produced, the goal is to “reset” a person’s metabolism to match their new, lower weight, and help them keep it there without staying on medication.
The early data is encouraging. The research is led by Dr. Shelby Sullivan, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center in Lebanon, New Hampshire.
Her team recruited 45 participants who had each lost at least 15% of their body weight (roughly 40 pounds on average) using tirzepatide (sold as Mounjaro and Zepbound), but were stopping the drug. 29 of the participants received the real procedure; the rest got a sham version.
The results were striking. Six months after stopping tirzepatide, the sham group had regained 40% more weight than those who got the real procedure.
Patients who had more of their gut resurfaced regained only about 7 pounds, keeping off more than 80% of their lost weight. And the gap between the two groups widened from month one to month six.
That trajectory is what excites the researchers. “It’s particularly encouraging that this benefit appears to increase over time rather than fade. Moreover, DMR behaves like a drug in terms of dose response. That gives us confidence that we’re targeting the right biology,” Sullivan said, per Digestive Disease Week.
It’s still early. The initial trial was small, and the team plans to keep tracking these patients’ weight going forward. A larger clinical trial with more than 300 participants is already underway (fully enrolled and randomized) with early results expected later this year.
If they echo the first round, the gut reset procedure could become the off-ramp that GLP-1 weight loss has been missing.
This article was created by content specialists using various tools, including AI.
